Zdrowie i gospodarka · 10/02/2012

FDA Releases Draft Guidance on Safety Data Collection for Late-Stage Clinical Investigations

The FDA has announced the availability of a draft guidance to help pharmaceutical companies determine the extent of safety data needed for late-stage clinical trials and post-approval studies, aiming to improve the quality of safety assessments without compromising trial results.